‘Digiceutical’ Collaboration May Advance Treatments for Schizophrenia and Multiple Sclerosis

‘Digiceutical’ Collaboration May Advance Treatments for Schizophrenia and Multiple Sclerosis

Pharma likes digital health as of late. It’s a big change compared to a few years back where a slew of companies stormed into the start-up landscape hoping to change healthcare forever. Pharma was too slow, and old school to make the changes needed in a rising technological revolution, or so it seemed.

The reality is that many of the initial innovations with digital health didn’t pan out, the hype has died down (unless you’re into artificial intelligence, then the sky’s the limit), and pharma has finally come around to paying attention to the field. It could be argued they’ve been watching this whole time, seeing who would come out of the fires of initial investments and make something of themselves, then pharma would swoop down to collaborate, offer an acquisition, or use their services.

Well, in an era of survival of the fittest in this start-up eat tech era, Novartis has stepped into the fray to sign-up with a digital health company. Their most recent deal is with Pear Therapeutics, a company aimed at providing FDA-cleared software interventions for disease management.1 They fill a niche with software geared to be adjunctive to pharmacological therapy or devices. Ideally, these would be used in clinical trials or prescribed for patient care. So far, current products approved include reSET, for substance use disorder; and reSET-O (currently in FDA submission) for opioid use disorder. Others presently set for FDA review are THRIVE, for schizophrenia; and reCALL, for PTSD. But looking forward, Pear Therapeutics is targetting oncology, MDD, insomnia, MS, inflammatory conditions, respiratory conditions, and Parkinson’s Disease.

Read More: PharmacyTimes.com

Leave a Reply